ReviewRheumatology (Oxford, England)2021
JAK1 inhibition and inflammatory bowel disease.
Review in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Musculoskeletal Ultrasound to Identify Subclinical Joint and Periarticular Involvement in Patients With Inflammatory Bowel Disease: A Systematic Literature Review.Frontiers in medicine · 2022Pooled it
- Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.Inflammatory bowel diseases · 2023Trial
- c-Myc-PANK3-EMT axis regulates the structure and function of intestinal barrier in ulcerative colitis.Journal of advanced research · 2026Article
- Identification of Novel Small-Molecule Janus Kinase 1 and 2 Inhibitors Through Structure-Based Virtual Screening,ACS omega · 2026Article
- Real-world effectiveness and safety of upadacitinib in Korean patients with inflammatory bowel disease: a single-center retrospective study.Intestinal research · 2026Article
- A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis.Crohn's & colitis 360 · 2026Article
- Advances in the Treatment of Ulcerative Colitis-From Conventional Therapies to Targeted Biologics and Small Molecules.International journal of molecular sciences · 2026Review
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- REAL-WORLD EXPERIENCE WITH JANUS KINASE INHIBITORS IN EXTRAINTESTINAL MANIFESTATIONS AND INFLAMMATORY BOWEL DISEASE IN COLOMBIA: A COMPARATIVE STUDY (JAKEIM-IBD STUDY).Arquivos de gastroenterologia · 2026Article
- State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A bibliometric and visual analysis of Jak1 to explore trends and frontiers.Frontiers in oncology · 2025Review
- A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib.PloS one · 2025Article
- Role of Aging in Ulcerative Colitis Pathogenesis: A Focus on ETS1 as a Promising Biomarker.Journal of inflammation research · 2025Article
- Tofacitinib for ulcerative colitis: A promising treatment option.World journal of gastroenterology · 2024Article
- Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy.Nucleic acid therapeutics · 2024Article
- Efficacy of Upadacitinib As a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series.Internal medicine (Tokyo, Japan) · 2024Article
- Review
- Upadacitinib as Rescue Therapy for the Treatment of Acute Severe Colitis in an Acute Care Setting.Digestive diseases and sciences · 2024Article
- Integrated single-cell and bulk RNA sequencing reveals CREM is involved in the pathogenesis of ulcerative colitis.Heliyon · 2024Article
- T helper cell 17/regulatory T cell balance regulates ulcerative colitis and the therapeutic role of natural plant components: a review.Frontiers in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary non-response and secondary loss of response remain a significant issue with the currently available treatment options for a significant proportion of patients with inflammatory bowel disease (IBD). There are multiple unmet needs in the IBD treatment algorithm and new treatment options are required. As our understanding of the pathogenesis of IBD evolves, new therapeutic targets are being identified. The JAK-STAT pathway has been extensively studied. Tofacitinib, a JAK1 inhibitor, is now licensed for use in the induction and maintenance of ulcerative colitis and there are a large number of molecules currently under investigation. These new small molecule drugs (SMDs) will challenge current treatment pathways at a time when clinical therapeutic outcomes are rapidly evolving and becoming more ambitious. This is a review of the current JAK1 inhibitors in IBD including the current evidence from clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.